Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Evopoint Biosciences Inc.
Evopoint Biosciences Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
Radiopharm Theranostics, Ltd
Terremoto Biosciences Inc.
Taiho Oncology, Inc.
GI Innovation, Inc.
Ensem Therapeutics
Mayo Clinic
Sun Yat-sen University
Eli Lilly and Company
Neonc Technologies, Inc.
Rutgers, The State University of New Jersey
Sichuan Enray Pharmaceutical Sciences Company
Ascendis Pharma A/S
Qurient Co., Ltd.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Amgen
Theravectys S.A.
Grey Wolf Therapeutics
TCRCure Biopharma Ltd.
Ocellaris Pharma, Inc.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Washington University School of Medicine
Tanabe Pharma America, Inc.
CRISPR Therapeutics
Sheba Medical Center
DualityBio Inc.
Laekna Limited
University of Arizona
Sichuan Baili Pharmaceutical Co., Ltd.
LigaChem Biosciences, Inc.
Institut Curie
Centre Leon Berard
Sensei Biotherapeutics, Inc.
Incyte Corporation
Cancer Research UK
Incyte Corporation
Yuhan Corporation
Agenus Inc.
Genexine, Inc.
University of California, Irvine
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Suzhou Suncadia Biopharmaceuticals Co., Ltd.